Global Blood Therapeutics, Inc. (GBT)
Stock Price:
$64.04 USD
-3.86 (-5.68%)
Updated Aug 6, 2020 4:00 PM EDT - Market closed
After-hours: $64.70 +0.66 (1.03%) Aug 6, 4:54 PM
Key Info
| Market Cap |
3.90B |
| Revenue (ttm) |
16.23M |
| Net Income (ttm) |
-286.39M |
| Shares Out |
60.94M |
| EPS (ttm) |
-4.89 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 6, 2020 |
| Last Price |
$64.04 |
| Previous Close |
$67.90 |
| Change ($) |
-3.86 |
| Change (%) |
-5.68% |
| Day's Open |
68.00 |
| Day's Range |
63.94 - 69.86 |
| Day's Volume |
1,546,103 |
| 52-Week Range |
39.95 - 87.54 |
More Stats
| Market Cap |
3.90B |
| Enterprise Value |
3.52B |
| Earnings Date (est) |
Nov 4, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
60.94M |
| Float |
53.42M |
| EPS (basic) |
-4.74 |
| EPS (diluted) |
-4.89 |
| FCF / Share |
-4.08 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
9.28M |
| Short Ratio |
8.20 |
| Short % of Float |
17.09% |
| Beta |
1.88 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
240.52 |
| PB Ratio |
8.09 |
| Revenue |
16.23M |
| Operating Income |
-301.75M |
| Net Income |
-286.39M |
| Free Cash Flow |
-249.05M |
| Net Cash |
387.45M |
| Net Cash / Share |
6.36 |
| Gross Margin |
12.70% |
| Operating Margin |
-1,859.65% |
| Profit Margin |
-600.10% |
| FCF Margin |
-1,534.89% |
| ROA |
-28.66% |
| ROE |
-53.86% |
| ROIC |
-62.50% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (17)
| Buy |
14 |
| Overweight |
0 |
| Hold |
3 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$108.38*
(69.24% upside)
Low
60.0
Current: $64.04
High
150.0
Target: 108.38
*Average 12-month price target from 16 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|
| Revenue | 2.11 | - | - | - | - | - | - |
| Gross Profit | 2.06 | - | - | - | - | - | - |
| Operating Income | -290 | -183 | -119 | -83.13 | -46.39 | -20.51 | -15.66 |
| Net Income | -267 | -174 | -117 | -82.47 | -46.36 | -20.81 | -18.12 |
| Shares Outstanding | 58.32 | 51.15 | 42.32 | 33.21 | 12.81 | 1.67 | 1.23 |
| Earnings Per Share | -4.57 | -3.41 | -2.76 | -2.48 | -3.95 | -14.20 | -16.14 |
| Operating Cash Flow | -194 | -135 | -93.02 | -67.72 | -30.89 | -20.12 | -14.70 |
| Capital Expenditures | -3.42 | -4.75 | -3.10 | -1.35 | -0.99 | -0.32 | -0.94 |
| Free Cash Flow | -198 | -140 | -96.12 | -69.08 | -31.88 | -20.44 | -15.64 |
| Cash & Equivalents | 612 | 480 | 316 | 147 | 149 | 52.21 | 0.00 |
| Total Debt | 146 | - | - | - | - | - | - |
| Net Cash / Debt | 466 | 480 | 316 | 147 | 149 | 52.21 | 0.00 |
| Assets | 796 | 618 | 357 | 202 | 152 | 55.76 | - |
| Liabilities | 217 | 44.84 | 37.92 | 16.08 | 11.18 | 2.92 | - |
| Book Value | 579 | 573 | 319 | 186 | 141 | -49.33 | - |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Global Blood Therapeutics, Inc. |
| Country |
United States |
| Employees |
352 |
| CEO |
Ted W. Love |
Stock Information
| Ticker Symbol |
GBT |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: GBT |
Description
Global Blood Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, Oxbryta (voxelotor) tablets, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating Oxbryta that has completed Phase III clinical trial in adult and adolescent patients with SCD. It is also evaluating the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase IIa clinical trial of adolescent and pediatric patients with SCD. The company has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD) and beta thalassemia. Global Blood Therapeutics, Inc. was founded in 2011 and is headquartered in South San Francisco, California.